Investigating how microglial signaling affects inflammation and degeneration in Alzheimer's disease

Unraveling microglial NOD2/RIPK2 signaling: Implications for neuroinflammation and neurodegeneration in Alzheimer's disease

NIH-funded research Johns Hopkins University · NIH-11102395

This study is looking at how certain signals in the brain might affect inflammation and cell damage in Alzheimer's disease, with the hope of finding new ways to help reduce these harmful effects for people living with the condition.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionJohns Hopkins University NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-11102395 on NIH RePORTER

What this research studies

This research focuses on understanding the role of specific signaling pathways in the brain, particularly how the NOD2/RIPK2 pathway influences inflammation and cell damage in Alzheimer's disease. By studying the interaction between amyloid-beta aggregates and microglial cells, the researchers aim to uncover the mechanisms that lead to neuroinflammation and neurodegeneration. The study employs advanced techniques to analyze protein interactions and assess the effects of manipulating these pathways in mouse models of Alzheimer's. The ultimate goal is to identify potential new treatments that could mitigate the harmful effects of neuroinflammation in patients with Alzheimer's disease.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline related to neurodegeneration.

Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that reduce neuroinflammation and slow the progression of Alzheimer's disease.

How similar studies have performed: Previous research has shown promising results in targeting neuroinflammatory pathways in Alzheimer's, indicating that this approach could be a viable avenue for treatment.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.